| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | AZYO | Class A Common Stock | Award | +70,053 | +139% | 120,519 | 21 Sep 2023 | Direct | F1, F2 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | AZYO | Warrants (rights to buy) | Award | +105,080 | 105,080 | 21 Sep 2023 | Class A Common Stock | 105,080 | $1.43 | Direct | F1, F3 |
| Id | Content |
|---|---|
| F1 | The reported securities are included within the 70,053 Units purchased by the reporting person for $1.4275 per Unit. Each Unit consists of one share of Class A Common Stock and one warrant to purchase one and one-half shares of Class A Common Stock. |
| F2 | Includes 901 shares of Class A Common Stock acquired under the Company's 2020 Employee Stock Purchase Plan. |
| F3 | The warrant expires upon the earlier of (a) 30 trading days after the clearance by the U.S. Food & Drug Administration of the issuer's CanGarooRM antibiotic-eluting biologic envelope or (b) September 21, 2028. |